ATRC

AtriCure Inc. Common Stock (ATRC)

Stock · NASDAQ · Health Care

$56.07as of 10/16/2026

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 13, 2026

BTIG raises AtriCure price target to $63. BTIG raised its price target on AtriCure to $63. The new target sits above the current analyst consensus of $54.89 and exceeds the stock’s recent 52‑week high of $61.70. This adjustment may influence market expectations as the company trades near its recent support level of $27.47.

Active signals

Support level
$27.47
Industry
Medical/Dental Instruments

What ATRC's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.

SignalTimesMedian 20-session returnHigher after 20 sessions
Volume Spike29+1.1%59%
Bollinger Band Breakdown24-0.8%50%
Bollinger Band Breakout19+3.9%58%
200-Day Moving Average TouchActive now15+3.5%67%
Any 20-session window (baseline)-0.6%47%

Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.

About ATRC

AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens a…

Sector
Health Care
Industry
Medical/Dental Instruments
Employees
1,350

Fundamentals

1-day range
$51.63$53.1
Market cap
$2.01B
P/E (trailing)
261.42
P/E (forward)
120.06
EPS (trailing)
$0.22
Dividend yield
—
Beta
1.23
Avg. volume
1.09M
52-week range
$25.36$61.7
Next earnings: October 27, 2026 · EPS estimate $0.01After Closeconfirmed

How AtriCure Inc. Common Stock Makes Money

Where the revenue actually goes — FY2025 annual results

market-wall.comTotalRevenue$534.53MSG&A$311.02M (58%)Cost of Revenue$133.75M (25%)R&D$99.21M (19%)Tax$1.28M (0%)ATRC

Source: 10-K filed Feb 19, 2026 · via SEC EDGAR / Finnhub

Gross Profit$400.78M(75%)
Operating Income-$9.45M(-2%)

Forecasts

9 analyst ratings

Buy 81%
Hold 19%
Sell 0%
1-year price forecast
High
$65
+15.9%
Median
$55
-1.9%
Low
$36
-35.8%

AtriCure Inc. Common Stock Competitors

Chosen by industry and closest market cap.

  • ATRC
    AtriCure Inc. Common Stock
    $56.07
    ▼ 2.96%
    Market cap $2.01BP/E 261.42
    $25.36$61.7
  • LMAT
    LeMaitre Vascular Inc. Common Stock
    $80.82
    ▼ 2.81%
    Market cap $1.85BP/E 29.17
    $78.22$118.01
  • NVCR
    NovoCure Limited Ordinary Shares
    $14.07
    ▼ 2.36%
    Market cap $1.83BP/E —
    $9.82$21.45
  • INSP
    Inspire Medical Systems Inc. Common Stock
    $68.79
    ▼ 1.90%
    Market cap $1.70BP/E 15.06
    $38.91$147.03
  • HTFL
    Heartflow Inc. Common Stock
    $48.29
    ▼ 5.14%
    Market cap $2.34BP/E —
    $20.13$54.32
  • UFPT
    UFP Technologies Inc. Common Stock
    $291.67
    ▼ 1.86%
    Market cap $2.41BP/E 31.50
    $173.86$338.71
  • KMTS
    Kestra Medical Technologies Ltd. Common Stock
    $27.24
    ▼ 5.02%
    Market cap $1.48BP/E —
    $17.34$30

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

Insider Activity

Insider Actions →
Acquired
26.3K
Disposed
79.6K

Institutional Ownership

March 31, 2026

Total shares held
46.73M
Total value held
$1.33B
Institutional holders
216
Top holders this quarter
  • Unknown4.04M
  • Unknown3.38M
  • Unknown3.26M
  • Unknown3.12M
  • Unknown2.16M
  • Unknown1.80M
  • Unknown1.67M
  • Unknown1.47M
  • Unknown1.30M
  • Unknown1.23M

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.